UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
For the quarterly period ended September 30, 2017 |
|
|
|
OR |
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-37686
BEIGENE, LTD.
(Exact name of registrant as specified in its charter)
Cayman Islands |
98-1209416 |
(State or other jurisdiction of |
(I.R.S. Employer |
c/o Mourant Ozannes Corporate Services |
|
94 Solaris Avenue, Camana Bay |
|
Grand Cayman |
|
Cayman Islands |
KY1-1108 |
(Address of principal executive offices) |
(Zip Code) |
+1 (345) 949 4123
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
|
Accelerated Filer |
☐ |
Non-accelerated filer |
☒ |
(Do not check if a smaller reporting company) |
Smaller reporting company |
☐ |
Emerging growth company |
☒ |
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 8, 2017, 591,072,330 ordinary shares, par value $0.0001 per share, were outstanding, of which 377,568,555 ordinary shares were held in the form of 29,043,735 American Depositary Shares, each representing 13 ordinary shares.
Quarterly Report on Form 10-Q
|
|
|
Page |
|
|
|
|
|
3 | ||
|
|
|
|
|
3 | ||
|
|
|
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
29 | |
|
|
|
|
|
47 | ||
|
|
|
|
|
48 | ||
|
|
|
|
|
48 | ||
|
|
|
|
|
48 | ||
|
|
|
|
|
49 | ||
|
|
|
|
|
120 | ||
|
|
|
|
|
120 | ||
|
|
|
|
|
120 | ||
|
|
|
|
|
120 | ||
|
|
|
|
|
121 | ||
|
|
|
|
|
124 |
2
BEIGENE, LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
|
|
|
|
As of |
|
||
|
|
|
|
September 30, |
|
December 31, |
|
|
|
Note |
|
2017 |
|
2016 |
|
|
|
|
|
$ |
|
$ |
|
|
|
|
|
(unaudited) |
|
(audited) |
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
208,510 |
|
87,514 |
|
Short-term investments |
|
5 |
|
548,925 |
|
280,660 |
|
Accounts receivable |
|
|
|
10,521 |
|
— |
|
Unbilled receivable |
|
|
|
170,950 |
|
— |
|
Inventories |
|
6 |
|
5,712 |
|
— |
|
Prepaid expenses and other current assets |
|
|
|
17,712 |
|
6,225 |
|
Total current assets |
|
|
|
962,330 |
|
374,399 |
|
Property and equipment, net |
|
7 |
|
55,322 |
|
25,977 |
|
Land use right, net |
|
8 |
|
12,251 |
|
— |
|
Intangible assets, net |
|
9 |
|
7,437 |
|
— |
|
Goodwill |
|
9 |
|
1,984 |
|
— |
|
Deferred tax assets |
|
10 |
|
7,684 |
|
768 |
|
Other non-current assets |
|
|
|
2,051 |
|
4,669 |
|
Total non-current assets |
|
|
|
86,729 |
|
31,414 |
|
Total assets |
|
|
|
1,049,059 |
|
405,813 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts payable |
|
|
|
35,168 |
|
11,957 |
|
Accrued expenses and other payables |
|
11 |
|
46,991 |
|
22,297 |
|
Deferred revenue, current portion |
|
|
|
9,132 |
|
— |
|
Tax payable |
|
10 |
|
2,852 |
|
804 |
|
Current portion of long-term bank loan |
|
14 |
|
9,018 |
|
— |
|
Total current liabilities |
|
|
|
103,161 |
|
35,058 |
|
Non-current liabilities: |
|
|
|
|
|
|
|
Long-term bank loan |
|
14 |
|
9,018 |
|
17,284 |
|
Shareholder loan |
|
15 |
|
140,311 |
|
— |
|
Deferred revenue, non-current portion |
|
|
|
29,477 |
|
|
|
Deferred tax liabilities |
|
10 |
|
1,859 |
|
— |
|
Other long-term liabilities |
|
|
|
744 |
|
564 |
|
Total non-current liabilities |
|
|
|
181,409 |
|
17,848 |
|
Total liabilities |
|
|
|
284,570 |
|
52,906 |
|
Commitments and contingencies |
|
24 |
|
|
|
|
|
Equity: |
|
|
|
|
|
|
|
Ordinary shares (par value of US$0.0001 per share; 9,500,000,000 shares authorized; 589,772,330 shares issued and outstanding as of September 30, 2017 (December 31, 2016: 9,500,000,000 shares authorized; 515,833,609 shares issued and outstanding)) |
|
|
|
59 |
|
52 |
|
Additional paid-in capital |
|
|
|
981,237 |
|
591,213 |
|
Accumulated other comprehensive income /(loss) |
|
20 |
|
38 |
|
(946) |
|
Accumulated deficit |
|
|
|
(231,194) |
|
(237,412) |
|
Total BeiGene, Ltd. shareholders’ equity |
|
|
|
750,140 |
|
352,907 |
|
Noncontrolling interest |
|
21 |
|
14,349 |
|
— |
|
Total equity |
|
22 |
|
764,489 |
|
352,907 |
|
Total liabilities and equity |
|
|
|
1,049,059 |
|
405,813 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
BEIGENE, LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
(Unaudited)
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||
|
|
|
|
September 30, |
|
September 30, |
|
||||
|
|
Note |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
|
|
$ |
|
$ |
|
$ |
|
$ |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
|
17 |
|
8,822 |
|
— |
|
8,822 |
|
— |
|
Collaboration revenue |
|
3 |
|
211,391 |
|
— |
|
211,391 |
|
1,070 |
|
Total revenues |
|
|
|
220,213 |
|
— |
|
220,213 |
|
1,070 |
|
Expenses |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales - product |
|
|
|
(1,944) |
|
— |
|
(1,944) |
|
— |
|
Research and development |
|
|
|
(87,660) |
|
(30,106) |
|
(177,678) |
|
(69,100) |
|
Selling, general and administrative |
|
|
|
(15,641) |
|
(4,722) |
|
(35,187) |
|
(11,760) |
|
Amortization of intangible assets |
|
|
|
(63) |
|
— |
|
(63) |
|
— |
|
Total expenses |
|
|
|
(105,308) |
|
(34,828) |
|
(214,872) |
|
(80,860) |
|
Income /(loss) from operations |
|
|
|
114,905 |
|
(34,828) |
|
5,341 |
|
(79,790) |
|
Interest (expense)/income, net |
|
|
|
(1,785) |
|
(75) |
|
(3,581) |
|
336 |
|
Changes in fair value of financial instruments |
|
12 |
|
— |
|
— |
|
— |
|
(1,514) |
|
(Loss)/gain on sale of available-for-sale securities |
|
|
|
— |
|
(137) |
|
10 |
|
(1,077) |
|
Other income/(expense), net |
|
|
|
1,103 |
|
(327) |
|
1,531 |
|
732 |
|
Income/(loss) before income tax expense |
|
|
|
114,223 |
|
(35,367) |
|
3,301 |
|
(81,313) |
|
Income tax benefit /(expense) |
|
10 |
|
3,061 |
|
(127) |
|
2,680 |
|
(306) |
|
Net income /(loss) |
|
|
|
117,284 |
|
(35,494) |
|
5,981 |
|
(81,619) |
|
Less: Net loss attributable to noncontrolling interest |
|
|
|
(102) |
|
— |
|
(237) |
|
— |
|
Net income /(loss) attributable to BeiGene, Ltd. |
|
|
|
117,386 |
|
(35,494) |
|
6,218 |
|
(81,619) |
|
Net income/(loss) per share attributable to BeiGene, Ltd. |
|
18 |
|
|
|
|
|
|
|
|
|
Basic (in dollars per share) |
|
|
|
0.21 |
|
(0.08) |
|
0.01 |
|
(0.21) |
|
Diluted (in dollars per share) |
|
|
|
0.20 |
|
(0.08) |
|
0.01 |
|
(0.21) |
|
Weighted-average shares used in net income/(loss) per share calculation |
|
18 |
|
|
|
|
|
|
|
|
|
Basic (in shares) |
|
|
|
547,546,656 |
|
428,137,509 |
|
527,329,985 |
|
383,472,372 |
|
Diluted (in shares) |
|
|
|
600,612,680 |
|
428,137,509 |
|
561,237,818 |
|
383,472,372 |
|
Net income /(loss) per American Depositary Share (“ADS”) |
|
|
|
|
|
|
|
|
|
|
|
Basic (in dollars per ADS) |
|
|
|
2.79 |
|
(1.08) |
|
0.15 |
|
(2.77) |
|
Diluted (in dollars per ADS) |
|
|
|
2.54 |
|
(1.08) |
|
0.14 |
|
(2.77) |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
BEIGENE, LTD.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
(Unaudited)
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||
|
|
September 30, |
|
September 30, |
|
||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
$ |
|
$ |
|
$ |
|
$ |
|
Net income /(1oss) |
|
117,284 |
|
(35,494) |
|
5,981 |
|
(81,619) |
|
Other comprehensive income /(loss), net of tax of nil: |
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
341 |
|
377 |
|
985 |
|
(13) |
|
Unrealized holding gain, net |
|
51 |
|
121 |
|
58 |
|
857 |
|
Comprehensive income /(loss) |
|
117,676 |
|
(34,996) |
|
7,024 |
|
(80,775) |
|
Less: Comprehensive loss attributable to noncontrolling interests |
|
(70) |
|
— |
|
(178) |
|
— |
|
Comprehensive income /(loss) attributable to BeiGene, Ltd. |
|
117,746 |
|
(34,996) |
|
7,202 |
|
(80,775) |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
BEIGENE, LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
(Unaudited)
|
|
|
|
Nine Months Ended September 30, |
||
|
|
Note |
|
2017 |
|
2016 |
|
|
|
|
$ |
|
$ |
Operating activities |
|
|
|
|
|
|
Net income /(loss) |
|
|
|
5,981 |
|
(81,619) |
Adjustments to reconcile net income/(loss) to net cash used in operating activities: |
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
|
2,704 |
|
1,436 |
Share-based compensation expense |
|
19 |
|
26,401 |
|
6,678 |
Changes in fair value of financial instruments |
|
|
|
— |
|
1,514 |
Loss on disposal of property and equipment |
|
|
|
85 |
|
— |
Non-cash interest expense |
|
|
|
4,796 |
|
118 |
Deferred income tax benefits |
|
|
|
(5,871) |
|
— |
Other non-cash expenses |
|
|
|
(10) |
|
1,077 |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
|
(10,521) |
|
— |
Unbilled receivable |
|
|
|
(170,950) |
|
— |
Inventories |
|
|
|
(5,712) |
|
— |
Prepaid expenses and other current assets |
|
|
|
(10,967) |
|
(2,183) |
Other non-current assets |
|
|
|
(635) |
|
(1,281) |
Accounts payable |
|
|
|
21,420 |
|
(1,839) |
Advances from customers |
|
|
|
— |
|
(1,070) |
Accrued expenses and other payables |
|
|
|
22,371 |
|
13,360 |
Tax payable |
|
|
|
1,122 |
|
294 |
Deferred revenue |
|
|
|
38,609 |
|
— |
Other long-term liabilities |
|
|
|
180 |
|
142 |
Net cash used in operating activities |
|
|
|
(80,997) |
|
(63,373) |
Investing activities |
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
(27,441) |
|
(15,440) |
Payment for the acquisition of land use right |
|
|
|
(12,354) |
|
— |
Cash acquired in business combination, net of cash paid |
|
4 |
|
19,916 |
|
— |
Purchase of available-for-sale securities |
|
|
|
(464,065) |
|
(193,996) |
Proceeds from sale or maturity of available-for-sale securities |
|
|
|
245,928 |
|
158,307 |
Investment in time deposits |
|
|
|
(50,061) |
|
— |
Net cash used in investing activities |
|
|
|
(288,077) |
|
(51,129) |
Financing activities |
|
|
|
|
|
|
Proceeds from public offering, net of underwriter discount |
|
|
|
189,191 |
|
169,409 |
Payment of public offering cost |
|
|
|
(674) |
|
(1,478) |
Proceeds from sale of ordinary shares, net of cost |
|
|
|
149,928 |
|
— |
Proceeds from long-term loan |
|
|
|
— |
|
12,161 |
Proceeds from short-term loan |
|
13 |
|
2,470 |
|
— |
Repayment of short-term loan |
|
13 |
|
(2,470) |
|
— |
Capital contribution from noncontrolling interest |
|
21 |
|
14,527 |
|
— |
Proceeds from shareholder loan |
|
15 |
|
132,757 |
|
— |
Proceeds from exercise of warrants and options |
|
|
|
— |
|
2,115 |
Proceeds from option exercises |
|
|
|
1,579 |
|
3 |
Net cash provided by financing activities |
|
|
|
487,308 |
|
182,210 |
Effect of foreign exchange rate changes, net |
|
|
|
2,762 |
|
(45) |
Net increase in cash and cash equivalents |
|
|
|
120,996 |
|
67,663 |
Cash and cash equivalents at beginning of period |
|
|
|
87,514 |
|
17,869 |
Cash and cash equivalents at end of period |
|
|
|
208,510 |
|
85,532 |
Supplemental cash flow disclosures: |
|
|
|
|
|
|
Income taxes paid |
|
|
|
1,429 |
|
25 |
Interest expense paid |
|
|
|
940 |
|
510 |
Non-cash activities: |
|
|
|
|
|
|
Discount provided on sale of ordinary shares for business combination |
|
4 |
|
23,606 |
|
— |
Conversion of Senior Promissory Note |
|
|
|
— |
|
14,693 |
Conversion of deferred rental |
|
|
|
— |
|
980 |
Conversion of convertible preferred shares |
|
|
|
— |
|
176,084 |
Exercise of warrants and options |
|
|
|
— |
|
3,687 |
Initial public offering costs accrued in accrued expenses and other payables |
|
|
|
— |
|
166 |
Acquisitions of equipment included in accounts payable |
|
|
|
1,482 |
|
319 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
BEIGENE, LTD.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of U.S. Dollar (“$”) and Renminbi (“RMB”), except for number of shares and per share data)
(Unaudited)
1. Organization
BeiGene, Ltd. (the “Company”) is a globally focused, commercial-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company’s development strategy is based on a novel translational platform that combines its unique access to internal patient-derived biopsies with strong oncology biology. The Company was incorporated under the laws of the Cayman Islands as an exempted company with limited liability on October 28, 2010. The Company completed its initial public offering (“IPO”) on the NASDAQ Global Select Market on February 8, 2016 and has completed subsequent follow-on public offerings and a sale of ordinary shares to Celgene Switzerland LLC (“Celgene Switzerland”) in a business development transaction, as described in Note 22, Shareholders’ Equity.
As at September 30, 2017, the Company’s subsidiaries are as follows:
|
|
|
|
|
|
Percentage of |
|
|
Date of |
Ownership by |
|||||||
Name of Company |
Place of Incorporation |
Incorporation |
the Company |
Principal Activities |
||||
BeiGene (Hong Kong) Co., Limited.("BeiGene HK") |
|
Hong Kong |
|
November 22, 2010 |
|
100 |
% |
Investment holding |
BeiGene (Beijing) Co., Ltd. ("BeiGene (Beijing)") |
|
The People’s Republic of China (“PRC” or “China”) |
|
January 24, 2011 |
|
100 |
% |
Medical and pharmaceutical research |
BeiGene AUS Pty Ltd. |
|
Australia |
|
July 15, 2013 |
|
100 |
% |
Clinical trial activities |
BeiGene 101 |
|
Cayman Islands |
|
August 30, 2012 |
|
100 |
% |
Medical and pharmaceutical research |
BeiGene (Suzhou) Co., Ltd. (“BeiGene (Suzhou)”) |
|
PRC |
|
April 9, 2015 |
|
100 |
% |
Medical and pharmaceutical research |
BeiGene USA, Inc.("BeiGene (USA)") |
|
United States |
|
July 8, 2015 |
|
100 |
% |
Clinical trial activities |
BeiGene (Shanghai) Co., Ltd. (“BeiGene (Shanghai)”) |
|
PRC |
|
September 11, 2015 |
|
100 |
% |
Medical and pharmaceutical research |
BeiGene Biologics Co., Ltd. ("BeiGene Biologics") |
|
PRC |
|
January 25, 2017 |
|
95 |
% |
Biologics manufacturing |
BeiGene Guangzhou Biologics Manufacturing Co., Ltd. ("BeiGene Guangzhou Factory") |
|
PRC |
|
March 3, 2017 |
|
95 |
% |
Biologics manufacturing |
BeiGene (Guangzhou) Co., Ltd. |
|
PRC |
|
July 11, 2017 |
|
100 |
% |
Medical and pharmaceutical research |
BeiGene Pharmaceutical (Shanghai) Co., Ltd. (BeiGene Pharmaceutical (Shanghai))* |
|
PRC |
|
December 15, 2009 |
|
100 |
% |
Medical and pharmaceutical consulting, marketing and promotional services |
BeiGene Switzerland GmbH |
|
Switzerland |
|
September 6, 2017 |
|
100 |
% |
Clinical trial activities and commercial |
BeiGene Ireland Limited |
|
Republic of Ireland |
|
August 11, 2017 |
|
100 |
% |
Clinical trial activities |
* On August 31, 2017, BeiGene HK acquired 100% of the equity interest of Celgene Pharmaceutical (Shanghai) Co., Ltd., which has been renamed BeiGene Pharmaceutical (Shanghai) Co., Ltd.
Manufacturing facility in Guangzhou
On March 7, 2017, BeiGene HK, a wholly owned subsidiary of the Company, and Guangzhou GET Technology Development Co., Ltd. (“GET”), entered into a definitive agreement to establish a commercial scale biologics manufacturing facility in Guangzhou, Guangdong Province, PRC.
On March 7, 2017, BeiGene HK and GET entered into an Equity Joint Venture Contract (the “JV Agreement”). Under the terms of the JV Agreement, BeiGene HK agreed to make an initial cash capital contribution of RMB200,000 and a subsequent contribution of one or more biologics assets in exchange for a 95% equity interest in BeiGene Biologics. GET agreed to provide a cash capital contribution of RMB100,000 to BeiGene Biologics, representing a 5% equity interest in BeiGene Biologics. In addition, on March 7, 2017, BeiGene Biologics entered into a contract with GET, under which GET agreed to provide a RMB900,000 loan (the “Shareholder Loan”) to BeiGene Biologics (see footnote 15). BeiGene Biologics is working to establish a biologics manufacturing facility in Guangzhou, through a wholly-owned subsidiary, the BeiGene Guangzhou Factory, to manufacture biologics for the Company and its subsidiaries.
7
On April 11, 2017, BeiGene HK, GET and BeiGene Biologics amended the JV agreement and the capital contribution agreement, among other things, to adjust the capital contribution schedules and adjust the initial term of the governing bodies and a certain management position. On April 13, 2017 and May 4, 2017, BeiGene HK made cash capital contributions of RMB137,830 and RMB2,415, respectively, into BeiGene Biologics. The remainder of the cash capital contribution from BeiGene HK to BeiGene Biologics will be paid by April 10, 2020. On April 14, 2017, GET made cash capital contributions of RMB100,000 into BeiGene Biologics. On April 14, 2017, BeiGene Biologics drew down the Shareholder Loan of RMB900,000 from GET (as further described in Note 15). As of September 30, 2017, the Company and GET held 95% and 5% equity interests in BeiGene Biologics, respectively.
As of September 30, 2017, the Company’s cash and cash equivalents included $91,577 of cash held by BeiGene Biologics to be used to build the commercial scale biologics facility and to fund research and development of the Company’s biologics drug candidates in China.
2. Summary of significant accounting policies
Basis of presentation and principles of consolidation
The accompanying condensed consolidated balance sheet as of September 30, 2017, the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2017 and 2016, the condensed consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016, and the related footnote disclosures are unaudited. The accompanying unaudited interim financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”).
The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period.
The condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.
Noncontrolling interests are recognized to reflect the portion of the equity of subsidiaries which are not attributable, directly or indirectly, to the controlling shareholders. The Company consolidates BeiGene Biologics under the voting model and recognizes GET’s equity interest as a noncontrolling interest in its consolidated financial statements.
Use of estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating sales rebates and returns allowance to arrive at net product revenues, identifying separate accounting units and estimating the best estimate of selling price of each deliverable in the Company’s revenue arrangements, estimating the fair value of net assets acquired in business combinations, assessing the impairment of long-lived assets, share-based compensation expenses, inventory, realizability of deferred tax assets and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.
8
Cash and cash equivalents
Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.
Accounts receivable
Trade accounts receivable are recorded at their invoiced amounts, net of allowances for doubtful accounts. An allowance for doubtful accounts is recorded when the collection of the full amount is no longer probable. In evaluating the collectability of receivable balances, the Company considers specific evidence including aging of the receivable, the customer’s payment history, its current creditworthiness and current economic trends. Accounts receivable are written off after all collection efforts have ceased. No allowance for doubtful accounts was recorded as of September 30, 2017. The Company regularly reviews the adequacy and appropriateness of an allowance for doubtful accounts.
As of September 30, 2017 the Company had $10,521 in accounts receivable as a result of the sale of the Company’s approved cancer therapies in the PRC, which are in-licensed from Celgene Coporation (“Celgene”), to the Company’s distributors.
Inventories are stated at the lower of cost and net realizable value, with cost determined on a weighted-average basis. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations.
Land use right, net
The land use right represents lease prepayments to the local Bureau of Land and Resources in Guangzhou. The land use right is carried at cost less accumulated amortization. Amortization is provided to write off the cost of lease prepayments on a straight-line basis over the shorter of the estimated usage periods or the terms of the land use, which is currently 50 years.
Business combination
The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805 (“ASC 805”): Business Combinations. The acquisition method of accounting requires all of the following steps: (i) identifying the acquirer, (ii) determining the acquisition date, (iii) recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree and (iv) recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of cost of acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree, is recorded as goodwill. If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statements of operations as a gain.
9
The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.
Goodwill and other intangible assets
Goodwill is as asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Company allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but is tested for impairment at least annually or more frequently if events or changes in circumstances would indicate a potential impairment.
For its goodwill impairment analysis, the Company operates with a single reporting unit. The Company tests goodwill for impairment on the last day of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of the reporting unit may exceed its fair value. The Company first assesses the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount, including goodwill, and performs a quantitative assessment if it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Under the quantitative test, if the carrying amount of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. The Company has an unconditional option to bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test.
Intangible assets acquired through business acquisitions are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Acquired identifiable intangible assets consist of the distribution rights with respect to approved cancer therapies licensed from Celgene, ABRAXANE®, REVLIMID®, and VIDAZA®, and its investigational agent CC-122 and are amortized on a straight-line basis over the estimated useful lives of the assets, which are 10 years.
Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Group evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available.
Revenue recognition
Product revenue
Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has transferred to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured, all performance obligations have been met, and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates , estimated product returns and other deductions. Provisions for estimated reductions to revenue are provided for in the same period the related sales are recorded and are based on the sales terms, historical experience and trend analysis.
10
Rebates are offered to distributors, consistent with pharmaceutical industry practices. The Company records a provision for rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include the level of distributor inventories, sales volumes and contract pricing and estimated acceptance of government pricing or reimbursement amounts (such as provincial acceptance of the National Reimbursement Drug List (“NRDL”) pricing in the PRC). The Company regularly reviews the information related to these estimates and adjust the provision accordingly.
The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third party sources, and actual returns history, as well as other factors, as appropriate. If the historical data the Company uses to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. Any changes from the historical trend rates are considered in determining the current sales return allowance.
Collaboration revenue
The Company recognizes revenues from research and development collaborative arrangements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC 605, Revenue Recognition, or ASC 605. The Company’s collaborative arrangements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC 605-25, Multiple-Element Arrangements. Pursuant to ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has "stand-alone value" to the customer. The collaborative arrangements do not include a right of return for any deliverable. The arrangement's consideration that is fixed or determinable, excluding contingent payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The relative selling price for each deliverable is determined using vendor specific objective evidence, or VSOE, of selling price or third-party evidence, or TPE, of selling price if VSOE does not exist. If neither VSOE nor TPE exists, the Company uses the best estimate of the selling price (“BESP”) for the deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.
Upfront non-refundable payments for licensing our intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. The Company acts as the principal under its arrangements and licensing intellectual property is part of its ongoing major or central operations. The license right is not contingent upon the delivery of additional items or meeting other specified performance conditions. Therefore, when stand-alone value of the license is determinable, the allocated consideration is recognized as collaboration revenue upon delivery of the license rights.
As the Company acts as the principal under its arrangements, and research and development services are also part of its ongoing major or central operations, it recognize the allocated consideration related to reimbursements of research and development costs as collaboration revenue when delivery or performance of such services occurs.
Product development, royalties and commercial event payments, collectively referred to as target payments, under collaborative arrangements are triggered either by the results of our research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Under ASC 605-28, Milestone Method of Revenue Recognition, an accounting policy election can be made to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. The Company elected not to adopt the milestone method of revenue recognition under ASC 605-28.
Targets related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based targets, the Company would account for development-based targets as collaboration
11
revenue upon achievement of the respective development target. Royalties based on reported sales of licensed products will be recognized as collaboration revenue based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. Targets related to commercial activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these targets would be achieved after the completion of our development activities, the Company would account for the commercial event targets in the same manner as royalties, with collaboration revenue recognized upon achievement of the target.
Fair value measurements
Fair value of financial instruments
Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts receivable, long-term bank loan, Shareholder Loan and accounts payable. As of September 30, 2017 and December 31, 2016, the carrying values of cash and cash equivalents, accounts receivable and accounts payable approximated their fair values due to the short-term maturity of these instruments. The short-term investments represented the available-for-sale debt securities and time deposits. The available-for-sale debt securities are recorded at fair value based on quoted prices in active markets with unrealized gain or loss recorded in other comprehensive income or loss. The long-term bank loan and Shareholder Loan approximate their fair values due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instruments of comparable maturities. The warrants issued prior to the IPO relating to the convertible promissory notes and the option to purchase shares by rental deferral were exercised in January 2016 and February 2016. The Company determined the exercise date fair value of the warrants and option using the intrinsic value, which equals to the difference between the share price at the IPO closing date and the exercise price, as the exercise dates were immediately prior to or very close to the IPO closing date.
The Company applies ASC topic 820 (“ASC 820”), Fair Value Measurements and Disclosures, in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.
Level 3 - Unobservable inputs which are supported by little or no market activity.
ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.
12
Financial instruments measured at fair value on a recurring basis
The following tables set forth assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016:
|
|
Quoted Price |
|
|
|
|
|
|
in Active |
|
Significant |
|
|
|
|
Market for |
|
Other |
|
Significant |
|
|
Identical |
|
Observable |
|
Unobservable |
|
|
Assets |
|
Inputs |
|
Inputs |
As of September 30, 2017 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
|
|
$ |
|
$ |
|
$ |
Short-term investment (note 5): |
|
|
|
|
|
|
U.S. Treasury securities |
|
498,864 |
|
— |
|
— |
Time deposits |
|
50,061 |
|
— |
|
— |
Cash equivalents: |
|
|
|
|
|
|
Money market funds |
|
51,928 |
|
— |
|
— |
Total |
|
600,853 |
|
— |
|
— |
|
|
Quoted Price |
|
|
|
|
|
|
in Active |
|
Significant |
|
|
|
|
Market for |
|
Other |
|
Significant |
|
|
Identical |
|
Observable |
|
Unobservable |
|
|
Assets |
|
Inputs |
|
Inputs |
As of December 31, 2016 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
|
|
$ |
|
$ |
|
$ |
Short-term investment (note 5): |
|
|
|
|
|
|
U.S. Treasury securities |
|
280,660 |
|
— |
|
— |
Cash equivalents: |
|
|
|
|
|
|
Money market funds |
|
44,052 |
|
— |
|
— |
Total |
|
324,712 |
|
— |
|
— |
Recent accounting pronouncements
In August 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2015-14, Revenue from Contracts with Customers-Deferral of the Effective Date (“ASU 2015-14”). The amendments in ASU 2015-14 defer the effective date of ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), issued in May 2014. According to the amendments in ASU 2015-14, the new revenue guidance in ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (“ASU 2016-08”), which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing (“ASU 2016-10”), which clarify guidance related to identifying performance obligations and licensing implementation guidance contained in ASU No. 2014-09. In May 2016, the FASB issued ASU No. 2016-12 , Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), which addresses narrow-scope improvements to the guidance on collectability, non-cash consideration, and completed contracts at transition and provides practical expedients for contract modifications at transition and an accounting policy election related to the presentation of sales taxes and other similar taxes collected from customers. The effective date for the amendment in ASU 2016-08, ASU 2016-10 and ASU 2016-12 are the same as the effective date of ASU No. 2014-09. The Company anticipates adopting the new standard under the modified retrospective approach, effective January 1, 2018. The Company is continuing to assess the potential impact that ASC 606 may have on its financial position and results of operations as it relates to its collaboration agreements with Celgene and Merck KGaA, Darmstadt Germany. The Company expects that certain of its accounting conclusions will require further judgment. Further, the Company is continuing to analyze the potential impacts of the adoption of the new standard on its condensed consolidated financial
13
statements and related disclosures. While the Company is still in the process of evaluating the impact of adoption on its existing collaboration agreements, the Company currently believes that the impact of adoption of the new standard to its financial statements will not be material. The Company will also continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may impact its current conclusions, and will expand its analysis to include any new revenue arrangements initiated prior to adoption.
In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires lessees to recognize assets and liabilities related to lease arrangements longer than 12 months on the balance sheet. This standard also requires additional disclosures by lessees and contains targeted changes to accounting by lessors. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. The Company is currently evaluating the financial statement impact of adoption.
In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company will adopt ASU 2016-16 in its first quarter of 2018 utilizing the modified retrospective adoption method. The ultimate impact of adopting ASU 2016-16 will depend on the balance of intellectual property transferred between its subsidiaries as of the adoption date. The Company will recognize incremental deferred income tax expense thereafter as these deferred tax assets are utilized.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations: Clarifying the Definition of a Business. The new standard requires an entity to evaluate if substantially all the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set would not be considered a business. The new standard also requires a business to include at least one substantive process and narrows the definition of outputs. The new standard is effective for interim and annual periods beginning on January 1, 2018, and may be adopted earlier. The Company elected to early adopt the updated guidance. The standard is applied prospectively to any transaction occurring on or after the adoption date. The Company evaluated the acquisition of 100% of the equity interests of Celgene Pharmaceutical (Shanghai) Co., Ltd. (“Celgene Shanghai”) under the new guidance, and determined that the transaction represents a business combination, as disclosed further in Note 4.
In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other: Simplifying the Test for Goodwill Impairment. This ASU simplifies the test for goodwill impairment by removing Step 2 from the goodwill impairment test. Companies will now perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value not to exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendments in this update are effective for goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted for goodwill impairment tests performed after January 1, 2017. The Company elected to early adopt this ASU, and there was no material impact to the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation: Scope of Modification Accounting. This standard provides clarity and reduces both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based payment award. The updated guidance is effective for interim and annual periods beginning after December 15, 2017, and early adoption is permitted. This ASU is not expected to have a material impact on the Company’s consolidated financial statements.
3. Research and development collaborative arrangements
To date, the Company’s collaboration revenue has consisted of 1) upfront license fees from its collaboration agreement with Celgene on the Company’s investigational anti-programmed cell death protein1 (“PD-1”) inhibitor,
14
BGB-A317 and 2) upfront license fees, reimbursed research and development expenses and milestone payments from its collaboration agreement with Merck KGaA, Darmstadt Germany on BGB-290 and BGB-283.
Celgene and Celgene Switzerland
On July 5, 2017, the Company entered into a license agreement with Celgene Switzerland pursuant to which the Company granted to the Celgene parties an exclusive right to develop and commercialize the Company’s PD-1 inhibitor, BGB-A317, in all fields of treatment, other than hematology, in the United States, Europe, Japan and the rest of world other than Asia (the “PD-1 License Agreement”). In connection with the closing of the transactions on August 31, 2017, the Company, Celgene and Celgene Switzerland amended and restated the PD-1 License Agreement (the “A&R PD-1 License Agreement”) to, among other things, clarify the parties’ responsibilities relating to the conducting and funding of certain global registration clinical trials and clarify the scope of the regulatory materials transferred by BeiGene to Celgene.
Under the terms of the A&R PD-1 License Agreement, Celgene agreed to pay the Company $263,000 in upfront non-refundable license fees, of which $92,050 was paid in the third quarter of 2017 and the remaining $170,950 is due in December 2017. In addition, subsequent to the completion of the research and development phase of the collaboration, the Company may be eligible to receive product development milestone payments based on the successful achievement of development and regulatory goals, commercial milestone payments based on the successful achievement of commercialization goals, and royalty payments based on a predetermined percentage of Celgene and Celgene Switzerland’s aggregate annual net sales of all products in their territory for a period not to exceed the latest of the expiration of the last valid patent claim, the expiration of regulatory exclusivity or 12 years from the date of the first commercial sale on a product-by-product and country-by-country basis. The Company allocated the $13,000 of upfront fees to the fair value of assets related to the Company’s acquisition of Celgene Shanghai, a wholly-owned subsidiary of Celgene Holdings East Corporation established under the laws of China, that was completed contemporaneously with the A&R PD-1 License Agreement.
In addition to the exclusive right to develop and commercialize BGB-A317, the terms of the A&R PD-1 License Agreement provide Celgene with the right to collaborate with the Company on the development of BGB-A317 for specified indications, including required participation on a joint development committee and a joint steering committee as well as a joint commercialization committee upon achievement of commercialization. The joint development and joint steering committees are formed by an equal number of representatives from the Company and Celgene and are responsible for reviewing and approving the development plan and budget for the development of BGB-A317 for clinical studies associated with specified indications. Celgene will reimburse the Company for certain research and development costs at a cost plus agreed upon markup for the development of BGB-A317 related to the clinical trials that Celgene opts into, as outlined in the development plan.
Under ASC 605, the Company identified the following deliverables of the collaboration agreement with stand-alone value, which are accounted for as separate units of accounting: (a) the license provided to Celgene for the exclusive right to develop and commercialize BGB-A317, in all fields of treatment, other than hematology, in the United States, Europe, Japan and the rest of world other than Asia (“the license”); and (b) the research and development services provided to Celgene to develop BGB-A317 within specified indications (“R&D services”). For each deliverable, the Company determined the BESP and allocated the non-contingent consideration of $250,000 to the units of accounting using the relative selling price method. The consideration allocated to the license was recognized upon transfer of the license to Celgene at contract inception and the consideration allocated to the R&D services will be recognized over the term of the respective clinical studies for the specified indications.
For the payments associated with the defined developmental, regulatory, and commercialization goals, the Company determined that upon achievement of the developmental, regulatory, and commercialization goals, such payments will be allocated to the separate deliverables using the initial allocation based on the relative selling price method. Further, the sales-based milestones and royalty payments will be recognized when reported sales are reliably measurable and collectability is reasonably assured.
15
For the three and nine months ended September 30, 2017, the Company recognized $211,391 as license revenue within collaboration revenue in the Company’s condensed consolidated statements of operations. The consideration allocated to the R&D services, $38,609, is recorded as deferred revenue in balance sheet as of September 30, 2017 and will be recognized over the term of the respective clinical studies for the specified indications.
Merck KGaA, Darmstadt Germany
In March 2017, the Company regained the worldwide rights to BGB-283 after Merck KGaA, Darmstadt Germany informed the Company that it would not exercise a continuation option under the parties’ collaboration agreement, and thus, that agreement has terminated in its entirety, except for certain provisions that will survive the termination.
Revenue recognized in the three and nine months ended September 30, 2016, was related to Phase 1 research and development fees from the Company’s BRAF inhibitor, in accordance with the collaboration agreement with Merck KGaA Darmstadt Germany. Phase 1 services were completed by mid-2016 and as a result, all of the advance payments received from the collaboration have been recognized. For the three and nine months ended September 30, 2017, the company did not recognize any research and development revenue, and for the three and nine months ended September 30, 2016, the Company recognized nil and $1,070, respectively, as research and development revenue within collaboration revenue in the Company’s condensed consolidated statements of operations.
The following table summarizes the components of total collaboration revenue recognized for the three and nine months ended September 30, 2017 and 2016:
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||
|
|
September 30, |
|
September 30, |
|
||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
$ |
|
$ |
|
$ |
|
$ |
|
License revenue |
|
211,391 |
|
— |
|
211,391 |
|
— |
|
Research and development revenue |
|
— |
|
— |
|
— |
|
1,070 |
|
Total |
|
211,391 |
|
— |
|
211,391 |
|
1,070 |
|
4. Business Combination
On August 31, 2017, BeiGene HK acquired 100% of the equity interests of Celgene Shanghai, a wholly-owned subsidiary of Celgene Holdings East Corporation established under the laws of the PRC. Celgene Shanghai is in the business of, among other things, providing marketing and promotional services in connection with certain pharmaceutical products manufactured by Celgene. The name of Celgene Shanghai has been changed to BeiGene Pharmaceutical (Shanghai).
On July 5, 2017, BeiGene and a wholly-owned subsidiary of Celgene, Celgene Logistics Sàrl (“Celgene Logistics”), entered into a license agreement pursuant to which BeiGene has been granted the right to exclusively distribute and promote Celgene’s approved cancer therapies, ABRAXANE®, REVLIMID®, and VIDAZA®, and its investigational agent CC-122 in clinical development (the “Distribution Rights”), in China excluding Hong Kong, Macau and Taiwan (the “Chinese License Agreement”). The China License Agreement became effective on August 31, 2017 contemporaneously with the closing of the acquisition of Celgene Shanghai and the A&R PD-1 License Agreement.
The Company evaluated the acquisition of the Celgene Shanghai equity and the distribution rights acquired under ASU No. 2017-01, Business Combinations: Clarifying the Definition of a Business. Because substantially all of the value of the acquisition did not relate to a similar group of assets and the business contained both inputs and processes necessary to manage products and provide economic benefits directly to its owners, it was determined that the acquisition represents a business combination. Therefore, the transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date.
16
Share Subscription Agreement
On August 31, 2017, the Company closed the sale of 32,746,416 of its ordinary shares to Celgene Switzerland for an aggregate cash price of $150,000, or $4.58 per ordinary share, or $59.55 per ADS, pursuant to the Share Subscription Agreement dated July 5, 2017 by and between BeiGene and Celgene Switzerland (the “Share Subscription Agreement”). See Note 22 for further description of the Share Subscription Agreement.
Determination of Purchase Price
The purchase price of Celgene Shanghai is calculated as $28,138, and is comprised of cash consideration of $4,532 and non-cash consideration of $23,606, related to the discount on ordinary shares issued to Celgene in connection with the Share Subscription Agreement. The discount was a result of the increase in fair value of the Company’s shares between the fixed price of $59.55 per ADS in the Share Subscription Agreement and the fair value per ADS as of August 31, 2017. The following summarizes the purchase price in the business combination (in thousands).
|
|
|
|
|
|
Purchase Price |
|
Cash paid to acquire Celgene Shanghai |
|
$ |
4,532 |
Discount on Share Subscription Agreement |
|
|
23,606 |
Total purchase price |
|
$ |
28,138 |
Purchase Price Allocation
The following table summarized the estimated fair values of assets acquired and liabilities assumed (in thousands):
|
|
Amount |
Cash and cash equivalents |
$ |
24,448 |
Other current assets |
|
518 |
Property and equipment, net |
|
204 |
Intangible assets |
|
7,500 |
Deferred tax asset |
|
1,069 |
Total identifiable assets |
|
33,739 |
Current liabilities |
|
(5,710) |
Deferred tax liability |
|
(1,875) |
Total liabilities assumed |
|
(7,585) |
Goodwill |
|
1,984 |
Total fair value of consideration transferred |
$ |
28,138 |
The Company’s accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The goodwill resulting from the business combination is primarily attributable to the assembled workforce of the acquired business. The goodwill attributable to the business combination is not deductible for tax purposes.
17
The following summarizes the business combination as presented on the statement of cash flows (in thousands):
Investing activities |
|
|
|
Cash acquired |
|
$ |
24,448 |
Cash paid to acquire Celgene Shanghai |
|
|
(4,532) |
Cash acquired in business combination, net of cash paid |
|
$ |
19,916 |
|
|
|
|
Non-cash activities |
|
|
|
Discount provided on sale of ordinary shares for business combination |
|
$ |
(23,606) |
5. Short-term investments
Short-term investments as of September 30, 2017 consisted of the following available-for-sale debt securities and time deposits:
|
|
|
|
Gross |
|
Gross |
|
Fair Value |
|
|
Amortized |
|
Unrealized |
|
Unrealized |
|
(Net Carrying |
|
|
Cost |
|
Gains |
|
Losses |
|
Amount) |
|
|
$ |
|
$ |
|
$ |
|
$ |
U.S. Treasury securities |
|
498,905 |
|
— |
|
41 |
|
498,864 |
Time deposits |
|
50,061 |
|
— |
|
— |
|
50,061 |
Total |
|
548,966 |
|
— |
|
41 |
|
548,925 |
Short-term investments as of December 31, 2016 consisted of the following available-for-sale debt securities:
|
|
|
|
Gross |
|
Gross |
|
Fair Value |
|
|
Amortized |
|
Unrealized |
|
Unrealized |
|
(Net Carrying |
|
|
Cost |
|
Gains |
|
Losses |
|
Amount) |
|
|
$ |
|
$ |
|
$ |
|
$ |
U.S. Treasury securities |
|
280,757 |
|
— |
|
97 |
|
280,660 |
Total |
|
280,757 |
|
— |
|
97 |
|
280,660 |
Contractual maturities of all debt securities as of September 30, 2017 were within one year. The Company does not consider the investment in U.S. Treasury securities to be other-than-temporarily impaired at September 30, 2017. The cost of securities sold is based on the specific identification method.
6. Inventories
The Company’s inventory balance of $5,712 as of September 30, 2017 consisted entirely of finished goods product purchased from Celgene for distribution in the PRC.
18
7. Property and equipment
Property and equipment consisted of the following:
|
|
As of |
|
||
|
|
September 30, |
|
December 31, |
|
|
|
2017 |
|
2016 |
|
|
|
$ |
|
$ |
|
Laboratory equipment |
|
14,612 |
|
7,536 |
|
Manufacturing equipment |
|
13,380 |
|
— |
|
Leasehold improvements |
|
12,758 |
|
9,446 |
|
Electronic equipment |
|
1,234 |
|
647 |
|
Office equipment |
|
1,135 |
|
449 |
|
Computer software |
|
713 |
|
317 |
|
Property and equipment, at cost |
|
43,832 |
|
18,395 |
|
Less accumulated depreciation |
|
(12,535) |
|
(7,473) |
|
Construction in progress |
|
24,025 |
|
15,055 |
|
Property and equipment, net |
|
55,322 |
|
25,977 |
|
Construction in progress as of September 30, 2017 of $24,025 primarily relates to the buildout of the Guangzhou manufacturing facility. Construction in progress as of December 31, 2016 primarily related to the BeiGene Suzhou manufacturing and laboratory facility that was put into service in the third quarter of 2017. In the three months ended September 30, 2017, assets totaling $21,400 related to the Suzhou facilities were transferred to laboratory equipment, manufacturing equipment and leasehold improvements from construction in progress. Depreciation expense for the three and nine months ended September 30, 2017 was $1,237 and $2,641, respectively. Depreciation expense for the three and nine months ended September 30, 2016 was $505 and $1,436, respectively.
8. Land use right, net
The land use right represents the land acquired for the purpose of constructing and operating the biologics manufacturing facility in Guangzhou. In 2017, the Company acquired the land use right from the local Bureau of Land and Resources in Guangzhou. The land use right is amortized over the remaining term of the right. The land use right asset as of September 30, 2017 and December 31, 2016 is summarized as follows:
|
|
As of |
|
||
|
|
September 30, |
|
December 31, |
|
|
|
2017 |
|
2016 |
|
|
|
$ |
|
$ |
|
Land use right, cost |
|
12,354 |
|
— |
|
Accumulated amortization |
|
(103) |
|
— |
|
Land use right, net |
|
12,251 |
|
— |
|
Amortization expense of the land use right for the three and nine months ended September 30, 2017 was $103, which was charged to construction in process. Amortization expense of the land use right for the three and nine months ended September 30, 2016 was nil.
As of September 30, 2017, expected amortization expense for the land use right is approximately $62 for the remainder of 2017, $247 in 2018, $247 in 2019, $247 in 2020, $247 in 2021 and $11,201 in 2022 and thereafter.
19
9. Intangible assets and Goodwill
Intangible assets outstanding as of September 30, 2017 and December 31, 2016 are summarized as follows:
|